Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naive Patients With Ulcerative Colitis.

ABSTRACT:

Background

Although studies have compared on-treatment effectiveness of infliximab and vedolizumab in patients with ulcerative colitis (UC), there has been limited comparison of treatment sequencing and long-term patient-centred outcomes.

Aim

To compare infliximab-first and vedolizumab-first strategy in biologic-naïve patients with UC.

Methods

We conducted a retrospective cohort study in biologic-naïve patients with UC who were treated first with either infliximab or vedolizumab between 2015 and 2021 and followed over 30 months following initiation. Primary outcomes were the number of hospitalisations, corticosteroid courses and serious infections with either strategy (regardless of switch to alternative therapies) within 30 months. We matched the groups 1:1 through c

SUBMITTER: Haynesworth A 

PROVIDER: S-EPMC12186699 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature